Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803631 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAOAMAOBTDP1DRD2 | |
| SCHEMBL15775835 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TDP1DRD2BRD4GFER | |
| SCHEMBL15775419 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1DRD2CA12CA1 | |
| SCHEMBL25014086 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAOAMAOBTDP1DRD2 | |
| SCHEMBL15775751 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TDP1DRD2CA12CA1 | |
| SCHEMBL5526591 | 0.78 | MAOA (0.48) | MAOAMAOBTDP1DRD2CA12 | |
| SCHEMBL23636844 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAOAMAOBTDP1DRD2 | |
| SCHEMBL16245563 | 0.76 | TDP1 (0.47) | ALDH1A1MAOAMAOBTDP1DRD2 | |
| SCHEMBL23637066 | 0.75 | MEN1 (0.45) | ALDH1A1TDP1DRD2BRD4 | |
| SCHEMBL25014637 | 0.75 | TDP1 (0.49) | ALDH1A1MAOAMAOBTDP1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | ALDH1A1 3874/4885MAOA 4502/4885MAOB 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.